On the basis of the fact that lipoprotein has a strong correlation with NAFLD progression and, counterintuitively that the treatment of MERTK+/hi M2c macrophages could reduce the level of “bad” lipoprotein, we measured the levels of the plasma lipids of each group. This evidence concerns the gene MERTK and metabolic dysfunction-associated steatotic liver disease.